These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33418497)

  • 1. Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19.
    Ison MG; Scheetz MH
    EBioMedicine; 2021 Jan; 63():103204. PubMed ID: 33418497
    [No Abstract]   [Full Text] [Related]  

  • 2. Favipiravir use for SARS CoV-2 infection.
    Boretti A
    Pharmacol Rep; 2020 Dec; 72(6):1542-1552. PubMed ID: 33108587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?
    Eloy P; Le Grand R; Malvy D; Guedj J
    EBioMedicine; 2021 Dec; 74():103663. PubMed ID: 34768087
    [No Abstract]   [Full Text] [Related]  

  • 4. [Favipiravir, a new concept of antiviral drug against influenza viruses].
    Reina J; Reina N
    Rev Esp Quimioter; 2017 Apr; 30(2):79-83. PubMed ID: 28176519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study.
    Dabbous HM; Abd-Elsalam S; El-Sayed MH; Sherief AF; Ebeid FFS; El Ghafar MSA; Soliman S; Elbahnasawy M; Badawi R; Tageldin MA
    Arch Virol; 2021 Mar; 166(3):949-954. PubMed ID: 33492523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options.
    Sreekanth Reddy O; Lai WF
    Chembiochem; 2021 Mar; 22(6):939-948. PubMed ID: 33031623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Favipiravir, an antiviral for COVID-19?
    Coomes EA; Haghbayan H
    J Antimicrob Chemother; 2020 Jul; 75(7):2013-2014. PubMed ID: 32417899
    [No Abstract]   [Full Text] [Related]  

  • 8. Favipiravir and COVID-19: A Simplified Summary.
    Ghasemnejad-Berenji M; Pashapour S
    Drug Res (Stuttg); 2021 Mar; 71(3):166-170. PubMed ID: 33176367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir.
    Takashita E; Ejima M; Ogawa R; Fujisaki S; Neumann G; Furuta Y; Kawaoka Y; Tashiro M; Odagiri T
    Antiviral Res; 2016 Aug; 132():170-7. PubMed ID: 27321665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fingernail lunula luminescence in COVID-19 patients: Is it a favipiravir-related reaction or a novel manifestation of coronavirus infection.
    Kutlu Ö; Yılmaz Ş
    Photodermatol Photoimmunol Photomed; 2021 Jul; 37(4):343-344. PubMed ID: 33480085
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of favipiravir for an end stage renal disease patient on maintenance hemodialysis infected with novel coronavirus disease 2019.
    Koshi E; Saito S; Okazaki M; Toyama Y; Ishimoto T; Kosugi T; Hiraiwa H; Jingushi N; Yamamoto T; Ozaki M; Goto Y; Numaguchi A; Miyagawa Y; Kato I; Tetsuka N; Yagi T; Maruyama S
    CEN Case Rep; 2021 Feb; 10(1):126-131. PubMed ID: 32940880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences.
    Shiraki K; Sato N; Sakai K; Matsumoto S; Kaszynski RH; Takemoto M
    Pharmacol Ther; 2022 Jul; 235():108121. PubMed ID: 35121001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size.
    Zhao H; Zhu Q; Zhang C; Li J; Wei M; Qin Y; Chen G; Wang K; Yu J; Wu Z; Chen X; Wang G
    Biomed Pharmacother; 2021 Jan; 133():110825. PubMed ID: 33378989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nasopharyngeal SARS-CoV-2 Viral Load Response among COVID-19 Patients Receiving Favipiravir.
    Manosuthi W; Jeungsmarn S; Okada P; Suwanvattana P; Wongboot W; Thawornwan U; Charoenpong L; Wiboonchutikul S; Uttayamakul S; Pongpirul WA; Wachirapan A; Warachit P
    Jpn J Infect Dis; 2021 Sep; 74(5):416-420. PubMed ID: 33518623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future of antivirals in COVID-19: The case of favipiravir.
    Kow CS; Ramachandram DS; Hasan SS
    Int Immunopharmacol; 2022 Feb; 103():108455. PubMed ID: 34959188
    [No Abstract]   [Full Text] [Related]  

  • 16. Favipiravir for the Treatment of Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Naveed A; Cheema HA; Shahid A; Umer M; Hussain HU; Rehman MEU; Singh H; Kurman JS; Sahra S; Ahmad F; Ahmad S; Iqbal S
    Am J Ther; 2024 Jul-Aug 01; 31(4):e478-e482. PubMed ID: 38260985
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of hydroxychloroquine and favipiravir on clinical course in outpatients with COVID-19.
    Ömeroğlu ŞK; Temel F; Altun D; Öztop B
    Turk J Med Sci; 2021 Dec; 51(6):2827-2834. PubMed ID: 34165273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favipiravir for COVID-19 in a Patient on Hemodialysis.
    Hirai D; Yamashita D; Seta K
    Am J Kidney Dis; 2021 Jan; 77(1):153-154. PubMed ID: 33011311
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19.
    Shahrbaf MA; Tabary M; Khaheshi I
    Cardiovasc Hematol Disord Drug Targets; 2021; 21(2):88-90. PubMed ID: 34387172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Favipiravir for the Treatment of COVID-19 Outpatients: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Cheema HA; Ali A; Ali M; Shahid A; Ghafoor MS; Ur Rehman ME; Sah R; Sahra S; Ahmad S
    Am J Ther; 2024 May-Jun 01; 31(3):e328-e331. PubMed ID: 37647511
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.